Lemon Balm for Cognitive Function

The most surprising finding in the entire lemon balm literature is the Kennedy 2003 demonstration that an anxiolytic herb can simultaneously improve cognition: the highest dose tested (1600 mg of dried leaf) improved memory performance and increased calmness. In a separate 2004 trial using the Defined Intensity Stressor Simulation (DISS), a laboratory stress test, Kennedy's group found that 600 mg raised calmness and that 300 mg sped up mathematical processing with no loss of accuracy — a paradoxical "calm alert" cognitive profile distinct from every other classical anxiolytic, including the benzodiazepines and the antihistamine sedatives. The mechanism is not settled. Some lemon balm extracts inhibit acetylcholinesterase (AChE), the enzyme targeted by the prescription Alzheimer's drugs donepezil, rivastigmine, and galantamine, in the test tube, but the leaf used in the Kennedy 2003 trial showed no cholinesterase inhibition and instead bound to nicotinic and muscarinic acetylcholine receptors. The clinical translation came with the Akhondzadeh 2003 double-blind randomized controlled trial (RCT) in 42 patients with mild-to-moderate Alzheimer's disease, demonstrating modest but statistically significant improvement on ADAS-cog and CDR scales over 4 months of lemon balm extract. This page covers the cognitive trials, the AChE inhibition mechanism, the comparison to prescription cholinesterase inhibitors, and what is known about lemon balm in mild cognitive impairment and early dementia.


Table of Contents

  1. The Paradoxical "Calm Alert" Profile
  2. Kennedy 2003: Cognitive Enhancement in Healthy Volunteers
  3. Acetylcholinesterase Inhibition: A Proposed Mechanism
  4. Nicotinic and Muscarinic Receptor Binding
  5. Akhondzadeh 2003: Lemon Balm in Mild-to-Moderate Alzheimer's
  6. Lemon Balm vs Donepezil, Rivastigmine, Galantamine
  7. The Lamiaceae Cognitive Family (Sage, Rosemary, Spearmint)
  8. Mild Cognitive Impairment Applications
  9. Combining Lemon Balm with Conventional Care
  10. Dosing for Cognitive Indications
  11. Cautions and Drug Interactions
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Paradoxical "Calm Alert" Profile

Almost every anxiolytic available in clinical medicine produces some degree of cognitive impairment as a side effect. Benzodiazepines impair attention, working memory, and psychomotor speed. Sedating antihistamines (diphenhydramine, hydroxyzine) impair attention and reaction time. Alcohol impairs essentially every cognitive domain. Even the selective serotonin reuptake inhibitors (SSRIs) — not classically sedating — produce measurable processing-speed slowing in some patients. The cognitive cost is the standard trade-off for anxiety relief.

Lemon balm is the rare exception. In the Kennedy 2004 cross-over trial described in detail in Anxiety Relief (18 healthy volunteers given single doses of 300 mg and 600 mg of a standardized lemon balm extract and a placebo during the DISS stress test):

In the separate Kennedy 2003 trial of dried leaf, the highest dose (1600 mg) improved memory performance and increased calmness at all postdose time points.

This is the "calm alert" profile — physiologically and subjectively calmer, but cognitively faster with no loss of accuracy, although in the 2004 trial the calming and the faster-processing results came from different doses. The combination is why lemon balm is discussed for the common situation of a person who needs to be calmer in order to perform well on a cognitively demanding task (presentation, exam, surgical procedure, important negotiation) but who cannot afford the cognitive cost of a benzodiazepine. No prescription anxiolytic reliably produces this profile.

The proposed mechanism behind the paradox combines gamma-aminobutyric acid-transaminase inhibition (raising GABAergic tone) with cholinergic effects (raising cholinergic tone): acetylcholinesterase inhibition by some extracts in the test tube, and nicotinic and muscarinic receptor binding by the leaf used in the 2003 trial. The two systems are partially complementary — GABAergic tone reduces the anxious hyperarousal that disrupts focused attention, while cholinergic tone enhances the attention itself. The result is reduced anxiety with preserved or improved cognitive performance.

Back to Table of Contents

Kennedy 2003: Cognitive Enhancement in Healthy Volunteers

The cognitive arm of the Kennedy 2003 trial deserves its own treatment because the cognitive findings were arguably more surprising than the anxiolytic findings. The trial was published in Neuropsychopharmacology as "Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (lemon balm) with human central nervous system (CNS) nicotinic and muscarinic receptor-binding properties."

The study first screened samples of lemon balm for human acetylcholinesterase inhibition and cholinergic receptor binding, then tested the most cholinergically active dried leaf. Twenty healthy young adults received single doses of 600, 1000 and 1600 mg of encapsulated dried leaf or a matching placebo at 7-day intervals in a cross-over format, and were tested before dosing and at 1, 3 and 6 hours afterwards. Cognitive outcome measures came from the validated Cognitive Drug Research computerized assessment battery:

The pattern of results was complex. The most notable effects were improved memory performance and increased calmness at all postdose time points for the highest (1600 mg) dose. Decrements in the speed of timed memory task performance and on a rapid visual information-processing task increased with decreasing dose, so the slowing appeared at the lower doses, not the highest. The authors concluded that doses at or above 1600 mg can improve cognitive performance and mood, and that different preparations from the same plant may behave differently depending on how the sample is prepared.

The earlier 2002 trial from the same group (Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA, Pharmacology Biochemistry and Behavior) used a different, standardized extract in 20 healthy young adults at single doses of 300, 600 and 900 mg. It found a sustained improvement in Accuracy of Attention after 600 mg, but time- and dose-specific reductions in both Secondary Memory and Working Memory factors; self-rated calmness rose at the earliest time points with the lowest dose, while alertness was significantly reduced at all time points after the highest dose. Both nicotinic and muscarinic binding of that extract in human cortex tissue were found to be low compared with previous studies, and the 2003 paper notes that it did not exhibit in vitro cholinergic receptor-binding properties. That is why the 2003 study screened leaf samples first: its chosen leaf displaced nicotine and scopolamine from nicotinic and muscarinic receptors in human cerebral cortex tissue (IC50 0.18 and 3.47 mg/ml), the binding that gave the 2003 trial its mechanistic title. An earlier screening study (Wake 2000) had found one accession of lemon balm among the most potent European memory herbs at displacing these ligands.

Back to Table of Contents

Acetylcholinesterase Inhibition: A Proposed Mechanism

Acetylcholine (ACh) is the principal neurotransmitter of the cholinergic system, with central roles in attention, working memory, declarative learning, and the consolidation of long-term memory. The cholinergic projections from the basal forebrain (nucleus basalis of Meynert, medial septum) to the cortex and hippocampus are among the earliest neural systems to degenerate in Alzheimer's disease, and the resulting cholinergic deficit is widely accepted as a major driver of the early cognitive symptoms.

The functional concentration of acetylcholine in cholinergic synapses depends on the balance between two processes:

  1. Acetylcholine synthesis and release — the presynaptic enzyme choline acetyltransferase (ChAT) synthesizes ACh from choline and acetyl-CoA, and the neurotransmitter is released into the synaptic cleft on neuronal firing
  2. Acetylcholine catabolism — acetylcholinesterase (AChE) is the synaptic enzyme that hydrolyzes ACh to choline and acetate, terminating the synaptic signal. AChE is one of the fastest enzymes known — it can catabolize 25,000 ACh molecules per second per active site.

Inhibiting AChE slows the catabolism, raising the standing concentration of ACh in the synapse and prolonging the duration of cholinergic signaling. This is the principal mechanism of all four U.S. Food and Drug Administration-approved Alzheimer's cholinesterase inhibitors:

Some lemon balm preparations inhibit AChE in the test tube. Dastmalchi and colleagues (2009) found that a lemon balm extract inhibited the enzyme in a time- and dose-dependent manner, and that its most potent fraction contained cis- and trans-rosmarinic acid and a rosmarinic acid derivative. Ferreira and colleagues (2006) found AChE inhibitory capacity higher than 50% in the essential oil fraction of lemon balm. But the screening done for the Kennedy 2003 trial found no cholinesterase inhibitory properties in the dried leaf used in that trial, which acted on nicotinic and muscarinic receptors instead. The potency of any lemon balm extract is far lower than that of donepezil (a designed pharmaceutical optimized for potent AChE inhibition), and which of these mechanisms, if any, produces the cognitive effects seen in people is not known.

Back to Table of Contents

Nicotinic and Muscarinic Receptor Binding

Beyond AChE inhibition, lemon balm extracts have demonstrated direct binding affinity for both classes of cholinergic receptor:

Receptor binding combined with the AChE inhibition seen in some extracts would give lemon balm a multi-point cholinergic enhancement profile that may explain why the clinical effects on cognition appear larger than would be predicted from the modest AChE inhibition alone. The combination is at least theoretically more pharmacologically interesting than the single-mechanism AChE inhibition of donepezil — it more closely resembles galantamine, which combines AChE inhibition with nicotinic receptor allosteric modulation.

Back to Table of Contents

Akhondzadeh 2003: Lemon Balm in Mild-to-Moderate Alzheimer's

The pivotal clinical trial demonstrating lemon balm's effect in actual Alzheimer's disease was published by Shahin Akhondzadeh and colleagues at the Roozbeh Psychiatric Hospital and Tehran University of Medical Sciences in 2003 (Journal of Neurology, Neurosurgery and Psychiatry). The study was a 16-week double-blind, parallel-group, placebo-controlled, randomized clinical trial in 42 patients (18 women, 24 men) aged 65 to 80 with mild-to-moderate Alzheimer's disease (AD), a score of 12 or more on the ADAS-cog and 2 or less on the Clinical Dementia Rating, run at three centres in Tehran.

Patients were randomized to a fixed dose of Melissa officinalis extract, 60 drops daily, or placebo for 16 weeks. Outcome measures at baseline, week 8, and week 16 were:

Results at week 16:

This trial is the principal evidence supporting clinical use of lemon balm in mild-to-moderate Alzheimer's. It was run at three centres with a modest sample size (42 patients) and a non-pharmaceutical-quality standardized extract, but the design is rigorous and the results are coherent with the mechanistic data from Kennedy.

A later placebo-controlled trial did not reproduce the cognitive result. In a 2020 Japanese 24-week double-blind trial (Noguchi-Shinohara and colleagues), 23 patients with mild dementia due to Alzheimer's disease took either placebo or a lemon balm extract giving 500 mg of rosmarinic acid a day. The extract was safe and well tolerated, with no serious adverse events, but there were no significant differences in cognitive measures. The Neuropsychiatric Inventory Questionnaire (NPI-Q) score, which tracks behaviour and mood symptoms, improved by 0.5 points on the extract and worsened by 0.7 points on placebo (P = 0.012), and no significant differences were seen in disease-related biomarkers.

A companion study from the same Iranian group, published earlier in 2003 in the Journal of Clinical Pharmacy and Therapeutics, found that Salvia officinalis (sage) extract (60 drops a day for 4 months, 42 patients) produced a significantly better outcome on cognitive function than placebo in mild-to-moderate AD — reinforcing the conclusion that the cognitive effect is a class effect of the Lamiaceae phenolic-rich herbs, not specific to lemon balm.

Back to Table of Contents

Lemon Balm vs Donepezil, Rivastigmine, Galantamine

The cholinesterase inhibitors used in conventional Alzheimer's care are modestly effective drugs — the typical effect size in 6-month clinical trials is approximately a 2-3 point improvement on the 70-point ADAS-cog scale (a 2006 Cochrane review of 13 randomized, double-blind, placebo-controlled trials of donepezil, galantamine or rivastigmine found an average of -2.7 points, 95% CI -3.0 to -2.3, and noted that none of the treatment effects are large) and a 1.5-2 point improvement on the 40-item Severe Impairment Battery in moderate-severe AD. The benefit translates to a delay of cognitive decline of approximately 6-9 months in responders, with no impact on disease modification or eventual outcomes.

Compared to prescription cholinesterase inhibitors, lemon balm:

Lemon balm has been discussed in three roles: as an adjunct to standard care, as an option for people who cannot tolerate the gastrointestinal side effects of cholinesterase inhibitors, and as a botanical option in very early mild cognitive impairment, where prescription cholinesterase inhibitors are not yet typically started. The trials do not show it replacing prescription AD therapy for people who tolerate and benefit from those drugs.

The combination of lemon balm with a prescription cholinesterase inhibitor is pharmacologically rational (both raise cholinergic tone, by complementary mechanisms) but adds risk of additive cholinergic side effects (nausea, diarrhea, vivid dreams, urinary urgency).

Back to Table of Contents

The Lamiaceae Cognitive Family (Sage, Rosemary, Spearmint)

Lemon balm is one member of a family of cognitively active Lamiaceae herbs that share substantial chemistry and overlapping mechanisms:

The shared chemistry suggests that broad culinary use of multiple Lamiaceae herbs may contribute to dietary cognitive support, consistent with the Mediterranean diet's observational association with reduced dementia risk. For targeted cognitive enhancement, lemon balm and sage have the strongest individual evidence; rosemary and spearmint have meaningful supporting evidence.

Back to Table of Contents

Mild Cognitive Impairment Applications

Mild cognitive impairment (MCI) is the diagnostic intermediate between normal age-related cognitive change and dementia. Patients with MCI have objective cognitive decline (typically on memory testing) that exceeds age expectations but do not meet functional criteria for dementia — they can still manage their finances, medications, and daily activities independently. Approximately 10-15% of MCI patients progress to dementia per year, but a substantial fraction remain stable or even improve.

Prescription cholinesterase inhibitors are not typically initiated in MCI — the trials in MCI populations have shown modest or no benefit on conversion to AD, and the side-effect burden is not justified by the marginal effect. This leaves a clinical gap: a patient with objective MCI who is concerned about cognitive trajectory and wants to do something, but for whom prescription therapy is not indicated.

Lemon balm has been proposed for this gap. The cognitive results of the Kennedy healthy-volunteer trials and the Akhondzadeh mild-AD trial support the hypothesis that lemon balm could be useful at the MCI stage, although the 2020 trial in mild Alzheimer's dementia found no difference in cognitive measures. The lifestyle-modification character of an herbal regimen (typically combined with sleep hygiene, exercise, Mediterranean-pattern diet, social engagement, cognitive activity) aligns with the broader multimodal intervention approach that has the best supporting evidence for delaying progression of MCI.

Practitioner regimens for mild cognitive impairment that include lemon balm typically combine:

Back to Table of Contents

Combining Lemon Balm with Conventional Care

For people with established mild-to-moderate AD already on a prescription cholinesterase inhibitor, practitioners who add lemon balm as an adjunct describe these points, most of them about the additive cholinergic potential:

For people on memantine (an N-methyl-D-aspartate (NMDA) receptor antagonist used in moderate-severe AD), the mechanisms of the two do not overlap.

Back to Table of Contents

Dosing for Cognitive Indications

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA (2002). Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacology Biochemistry and Behavior. 72(4):953-64. — PubMed PMID: 12062586
  2. Kennedy DO, Wake G, Savelev S, Tildesley NT, Perry EK, Wesnes KA, Scholey AB (2003). Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology. 28(10):1871-81. — PubMed PMID: 12888775
  3. Kennedy DO, Little W, Scholey AB (2004). Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosomatic Medicine. 66(4):607-13. — PubMed PMID: 15272110
  4. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M (2003). Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. Journal of Neurology, Neurosurgery and Psychiatry. 74(7):863-6. — PubMed PMID: 12810768
  5. Noguchi-Shinohara M, Ono K, Hamaguchi T, Nagai T, Kobayashi S, Komatsu J, Samuraki-Yokohama M, Iwasa K, Yokoyama K, Nakamura H, Yamada M (2020). Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. Scientific Reports. 10(1):18627. — PubMed PMID: 33122694
  6. Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E (2000). CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. Journal of Ethnopharmacology. 69(2):105-14. — PubMed PMID: 10687867
  7. Dastmalchi K, Ollilainen V, Lackman P, Boije af Gennäs G, Dorman HJ, Järvinen PP, Yli-Kauhaluoma J, Hiltunen R (2009). Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorganic and Medicinal Chemistry. 17(2):867-71. — PubMed PMID: 19070498
  8. Ferreira A, Proença C, Serralheiro ML, Araújo ME (2006). The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. Journal of Ethnopharmacology. 108(1):31-7. — PubMed PMID: 16737790
  9. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M (2003). Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 28(1):53-9. — PubMed PMID: 12605619
  10. Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, Scholey AB (2003). Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacology Biochemistry and Behavior. 75(3):669-74. — PubMed PMID: 12895685
  11. Kennedy DO, Scholey AB (2006). The psychopharmacology of European herbs with cognition-enhancing properties. Current Pharmaceutical Design. 12(35):4613-23. — PubMed PMID: 17168769
  12. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS (1999). Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. Journal of Pharmacy and Pharmacology. 51(5):527-34. — PubMed PMID: 10411211
  13. Howes MJ, Houghton PJ (2003). Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacology Biochemistry and Behavior. 75(3):513-27. — PubMed PMID: 12895669
  14. Birks J (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2006(1):CD005593. — PubMed PMID: 16437532
  15. Ferris S, Karantzoulis S, Somogyi M, Meng X (2013). Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis. Alzheimer's Research and Therapy. 5(6):63. — PubMed PMID: 24351447
  16. Ozarowski M, Mikolajczak PL, Bogacz A, Gryszczynska A, Kujawska M, Jodynis-Liebert J, et al. (2013). Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia. 91:261-271. — PubMed PMID: 24080468
  17. Shakeri A, Sahebkar A, Javadi B (2016). Melissa officinalis L. - A review of its traditional uses, phytochemistry and pharmacology. Journal of Ethnopharmacology. 188:204-28. — PubMed PMID: 27167460

PubMed Topic Searches

  1. PubMed: Melissa AChE memory
  2. PubMed: Lemon balm Alzheimer's
  3. PubMed: Lamiaceae cognitive
  4. PubMed: AChE inhibitors AD
  5. PubMed: Sage cognitive memory
  6. PubMed: MCI herbal interventions
  7. PubMed: Calm-alert anxiolytic herbals

Back to Table of Contents

Connections

Back to Table of Contents